Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford
GlycoSciences and marketed by Actelion and is used primarily to treat type I ...
Lancet Neurol. 2007 Sep;6(9):765-72. Miglustat for treatment of Niemann-Pick C
disease: a randomised controlled study. Patterson MC(1), Vecchio D, Prady H, ...
The usual dose of Zavesca® in adult NP-C patients was 200 mg miglustat three
times a day, and was adjusted according to body surface area in pediatric NP-C ...
Zavesca (miglustat capsules, 100 mg) is an inhibitor of the enzyme
glucosylceramide synthase, which is a glucosyl transferase enzyme responsible
for the first ...
Each capsule contains 100 mg miglustat. For the full list of excipients, see section
6.1. 3. PHARMACEUTICAL FORM. Hard capsule. White capsules with “OGT ...
Miglustat reduces the biosynthesis of glucosylceramide from ceramide ...
Zavesca contains 100 mg of miglustat as active ingredient and it is presented in
Oct 20, 2015 ... Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics
(SPC) by Actelion Pharmaceuticals UK Ltd.
Dec 27, 2012 ... Miglustat (Zavesca®; Actelion Pharmaceuticals) is an orally active iminosugar
which reversibly inhibits UDP-glucosylceramide synthase – the ...
Jun 7, 2012 ... Miglustat can improve or stabilize neurological manifestations in paediatric
patients with the late-infantile and juvenile-onset forms of NP-C.
film (dried in situ). Synonym: Miglustat, NB-DNJ. SDS. CAS Number 72599-27-0.
Empirical Formula (Hill Notation) C10H21NO4. Molecular Weight 219.28.